Leede Financial Weighs in on TSE:MDP FY2026 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities researchers at Leede Financial decreased their FY2026 earnings per share (EPS) estimates for Medexus Pharmaceuticals in a research note issued to investors on Friday, November 8th. Leede Financial analyst D. Loe now forecasts that the company will earn $0.22 per share for the year, down from their previous forecast of $0.23. Leede Financial has a “Speculative Buy” rating and a $8.25 price target on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2027 earnings at $0.60 EPS.

MDP has been the subject of a number of other reports. Stifel Canada raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Monday, August 12th. Stifel Nicolaus lifted their price target on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a “buy” rating in a report on Thursday, August 22nd.

Medexus Pharmaceuticals Price Performance

TSE MDP opened at C$2.03 on Monday. Medexus Pharmaceuticals has a 1 year low of C$1.44 and a 1 year high of C$3.16. The company has a market capitalization of C$49.80 million, a PE ratio of 40.60 and a beta of 1.96. The company has a fifty day moving average of C$2.55 and a two-hundred day moving average of C$2.18.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.